Recombinant Human FABP4 Protein

Beta LifeScience SKU/CAT #: BL-3175PS

Recombinant Human FABP4 Protein

Beta LifeScience SKU/CAT #: BL-3175PS
Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Tag N/A
Host Species Human
Synonym Fatty acid-binding protein adipocyte, AFABP, Fatty acid-binding protein 4, Adipocyte lipid-binding protein, ALBP, A-FABP, FABP4.
Background Adipocyte fatty acid binding protein FABP4 is a 15 kDa member of the intracellular fatty acid binding protein (FABP) family, which is known for the ability to bind fatty acids and related compounds (bile acids or retinoids) in an internal cavity. FABP4 is expressed in a differentiation-dependent fashion in adipocytes and is a critical gene in the regulation of the biological function of these cells.In mice, targeted mutations in FABP4 provide significant protection fromIR in the context of both dietary and genetic obesity. Adipocytes obtained from FABP4-deficient mice also have reduced efficiency of ipolysis in vitro and in vivo, and these mice exhibited moderately improved systemic dyslipidemia. Recent studies also demonstrated FABP4 expression in macrophages upon differentiation and activation. In these cells, FABP4 modulates inflammatory responses and cholesterol ester accumulation, and total or macrophage-specific FABP4 deficiency confers dramatic protection against atherosclerosis in the apoE-/- mice. These results indicate a central role for FABP4 in the development of major components of the metabolic syndrome through its distinct actions in adipocytes and macrophages.
Description The Human FABP4 expressed from Human Adipose Tissue has a molecular weight of 14.587kDa (calculated without glycosylation) containing 131a.a. residues.
Source Human Adipose Tissue
AA Sequence CDAFVGTWKL VSSENFDDYM KEVGVGFATR KVAGMAKPNM IISVNGDVIT IKSESTFKNT EISFILGQEF DEVTADDRKV KSTITLDGGV LVHVQKWDGK STTIKRKRED DKLVVECVMK GVTSTRVYER A.
Purity >85.0% as determined by SDS-PAGE.
Endotoxin <1.0 EU per μg by the LAL method.
Formulation FABP4 protein filtered (0.4µm) and lyophilized in 0.5mg/ml in 0.05M phosphate buffer and 0.075M NaCl, pH 6.5.
Stability Recombinant protein is stable for 12 months at -70°C
Usage For Research Use Only
Storage Store lyophilized protein at -20°C. Aliquot the product after reconstitution to avoid repeated freezing/thawing cycles. Reconstituted protein can be stored at 4°C for a limited period of time; it does not show any change after two weeks at 4°C.

Target Details

Target Function Lipid transport protein in adipocytes. Binds both long chain fatty acids and retinoic acid. Delivers long-chain fatty acids and retinoic acid to their cognate receptors in the nucleus.
Subcellular Location Cytoplasm. Nucleus.
Protein Families Calycin superfamily, Fatty-acid binding protein (FABP) family
Database References

Gene Functions References

  1. FABP4 shows potential as a novel biomarker for diabetic retinopathy prediction in Chinese patients with type 2 diabetes (T2DM), and strict glycemic control and more frequent retinal examination should be highlighted for T2DM patients with the highest quartile range of FABP4. PMID: 29305311
  2. association between serum FABP4 concentrations and sarcopenia in chronic hemodialysis patients PMID: 29935964
  3. intermittent high glucose potentiates A-FABP activation and inflammatory responses via TLR4/p-JNK signaling in THP-1 cells PMID: 29850615
  4. High serum A-FABP concentration is associated with peripheral arterial disease in women, but not men, with type 2 diabetes mellitus. PMID: 28303680
  5. FABP4 from adipocytes mediate adipocyte-cholangiocarcinoma interactions that are crucial for the invasion, migration and epithelial-mesenchymal transition of cholangiocarcinoma cells PMID: 29237483
  6. Compared with the low arterial stiffness group, the high arterial stiffness group had higher values for age, systolic blood pressure, pulse pressure, duration of kidney transplantation and serum A-FABP PMID: 28660445
  7. Blood FABP4 is a biomarker for metabolic syndrome and cardiovascular disease independently of HIV status and antiretroviral therapy. PMID: 29304747
  8. Increased FABP4 blood level is a biomarker of lead exposure in women. PMID: 29264639
  9. ubiquitylation destabilizes the fold of two proteins, FKBP12 and FABP4 PMID: 27991582
  10. Compared to control group, breast cancer patients show higher FABP4 and FABP5 blood levels. Our data suggest that, particularly, circulating FABP4 levels could be considered a new independent breast cancer biomarker. Our work translates basic science data to clinic linking the relationship between adipose tissue and lipid metabolism to breast cancer. PMID: 28701570
  11. findings reveal a pro-angiogenic role of FABP4 in first trimester placental trophoblast cells and its regulation may have impact in placental physiology. PMID: 28620819
  12. A-FABP concentration was an independent predictor of cardiovascular events in patients with stable angina undergoing percutaneous coronary intervention. PMID: 29017449
  13. Ectopic expression and secretion of FABP4 in vascular endothelial cells contribute to neointima formation after vascular injury. PMID: 28903937
  14. Elevated A-FABP concentration could be a predictor for MetS and arterial stiffness in hypertensive patients PMID: 28860092
  15. The present study demonstrated that the androgen was correlated with the serum A-FABP levels negatively in men, but positively in women. PMID: 27270834
  16. Increased second trimester plasma FABP4 independently predicted GH/PE in GDM patients PMID: 29394285
  17. our research demonstrated that high FABP3 or FABP4 expression had strong prognostic value for overall survival in non-small cell lung cancer PMID: 27323829
  18. The distribution of genotype frequencies in the assessed women (PON1 Q192R polymorphism) was QQ = 20%, QR = 48% and RR = 32%. Significantly higher serum FABP4 levels were found in women with genotype QR/RR (20.6 +/- 2.20 ng/mL), when compared with the levels found in the QQ group (12.8 +/- 1.70 ng/mL) (p = .004). PMID: 27712128
  19. serum A-FABP levels were increased significantly in normoglycemic individuals with a first-degree family history of diabetes; the use of serum A-FABP as a biomarker in the first-degree relatives of patients with diabetes may result in overestimation of the risk of obesity-induced metabolic disease and cardiovascular disease PMID: 27534843
  20. Findings in the dorsolateral prefrontal cortex in schizophrenia provide evidence of altered proteins involved in synaptic function (FABP4), cytoarchitecture organization (NEFH), and circadian molecular clock signaling (CSNK1E), which may be contributing to the cognitive and/or negative symptoms in this disorder. FABP4, CSNK1E and NEFH could become potentially useful biomarkers for schizophrenia. PMID: 27236410
  21. Circulating levels of AFABP and EFABP are not decreased in Lipodystrophy despite adipose tissue loss in contrast to other adipokines including leptin and adiponectin. PMID: 28088613
  22. Taken together, PPAR gamma and FABP4 gene expression levels in PBMCs [peripheral blood mononuclear cells] may be indicators of metabolic factors and body composition components. PMID: 27563749
  23. eFABP4 induces ER stress and potentiates the effect of linoleic acid in HepG2 cells, suggesting that FABP4 could be a link between obesity-associated metabolic abnormalities and hepatic insulin resistance mechanisms PMID: 27155388
  24. Increased second-trimester FABP4 independently predicted pre-eclampsia in women with type 1 diabete and significantly improved reclassification and discrimination. PMID: 27630211
  25. High levels of FABP4 are significantly related to stroke risk and severity, independent from other traditional and emerging risk factors, suggesting that they may play a role in stroke pathogenesis. PMID: 28781090
  26. We found that serum FABP4 concentration were associated with insulin resistance and secretion in type 2 diabetes mellitus. This suggests that FABP4 may play an important role in glucose homeostasis. PMID: 28654680
  27. High FABP4 expression is associated with ovarian cancer. PMID: 27568980
  28. AFABP levels were higher in neonates compared with adults. Preterm infants had higher AFABP levels compared with full-term infants. Among full-term infants, AFABP levels in SGA infants were lower, compared with appropriate for gestational age and large for gestational age infants. PMID: 28324040
  29. Exogenous FABP4 plays a key role in tumor proliferation and activates the expression of fatty acid transport proteins in MCF-7 breast cancer cells. PMID: 27061264
  30. High FABP4 expression is associated with Acute Monocytic Leukemia. PMID: 28108519
  31. FABP4 over-expression in cardiomyocytes can aggravate the development of cardiac hypertrophy through the activation of ERK signal pathway. PMID: 27294862
  32. Results show that serum FABP4 levels were significantly increased in patients with psoriasis. PMID: 27864793
  33. secreted FABP4 and FABP5 from adipocytes as adipokines differentially affect transcriptional and metabolic regulation in ADSC near adipocytes PMID: 27936164
  34. FABP4 locally produced by epicardial/perivascular fat and macrophages in vascular plaques contributes to the development of coronary atherosclerosis. PMID: 27013610
  35. Elevated levels of FABP4 are associated with higher cardiovascular mortality among men with type 2 diabetes. PMID: 27609367
  36. These genes should be at the downstream of signal pathways and be regulated by the 23 genes identified before. Our findings may provide a unique new model for studying the molecular control of cattle cross-talk between adipose and skeletal muscle. PMID: 27856250
  37. higher serum A-FABP level is positively associated with MetS in type 2 DM patients PMID: 28042581
  38. FABP4 level was independently associated with gender, adiposity, renal dysfunction, and levels of cholesterol. PMID: 27241838
  39. FABP4 DNA hypomethylation induced by Hcy may be involved in the overexpression of FABP4, thereby inducing cholesterol accumulation in macrophages. PMID: 27221153
  40. Study found that the fasting insulin and age-adjusted AFABP concentrations were significantly higher in the gestational diabetes mellitus group of women compared with the normal glucose tolerance participants in the mid- and late stages of pregnancy. PMID: 27181269
  41. mTOR/FABP4 signaling pathway directly regulates the proliferation of endothelial cells in hemangioma. Rapamycin and inhibitors of FABP4 have therapeutic potential for treating infantile hemangiomas. PMID: 27914823
  42. Results suggested that the expression of a lipid metabolism-related gene and an important SNP in the 3'-UTR of FABP4 are associated with TNBC prognosis. PMID: 26959740
  43. In multiple linear regression stepwise analysis, BMI, HbA1C, and HOMA-IR were significantly independent determinants for A-FABP. BMI, HbA1C, and HOMA-IR are independently associated with A-FABP in obese subjects with newly diagnosed type 2 diabetes. A-FABP may be related to insulin resistance and inflammation in type 2 diabetes and concomitant obesity. PMID: 27819006
  44. The increase in placental FABP4 expression in preeclampsia may affect the function of trophoblast, and this increase may have a role in the pathogenesis of preeclampsia. PMID: 26992681
  45. our findings set up a novel mechanism for FABP4, adipsin and adiponectin through gut microbiota mediating expression in gut Paneth cells. PMID: 26687459
  46. results underline a gender difference in FABP4 secretion in stable COPD patients. PMID: 26823558
  47. Increased FABP4 level showed increased risk for reduced lung function in subjects with normal ventilatory function. PMID: 26887419
  48. High FABP expression is associated with Sepsis. PMID: 27089280
  49. Serum irisin might exert antagonistic effects on FABP4 in the middle-aged Chinese population. PMID: 26752184
  50. Urinary FABP4 level is independently correlated with level of albuminuria and possibly predicts yearly decline of estimated glomerular filtration rate. Urinary FABP4 would be a novel biomarker of glomerular damage. PMID: 25506691

FAQs

Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.

Recently viewed